GC Biopharma Corp (GC Biopharma), formerly GC Pharma, is a biopharmaceutical company that focuses on the development, manufacture, and distribution of pharmaceutical products. The company is primarily engaged in the manufacture and sale of pharmaceutical products, including blood products, vaccines, prescription drugs, and over-the-counter (OTC) preparations.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities are focused on developing plasma derivatives, recombinants, cell therapies, and vaccines for the treatment of Hemophilia A and B, Hunter syndrome, oncology, immunology, cell therapy, and other diseases. The company guides projects from early discovery to clinical trials, leveraging expertise in plasma protein production, recombinant protein technology, vaccine development, and next-generation mRNA/LNP platforms to build a pipeline of treatments. The company’s major product line which is in Phase III product candidates includes GC5107D for pediatric primary immunodeficiency and MG1111D for the treatment of Varicella. Its Phase II product candidates include MG1120A to treat Shingles and GC3111B for tetanus, diphtheria, and Pertusis. GC Biopharma conducts its R&D activities at a global R&D center located in Yongin, Gyeonggi, South Korea. In FY2024, the company spent KRW166,198 million on its R&D activities, which accounted for 9.9% of the company’s total revenue. The company works in partnerships and research collaborations with biotechnology start-ups, universities, research organizations, academia, and global leading companies to develop new drug candidates.